Perrigo Co. (NYSE:PRGO) has been assigned a consensus rating of “Hold” from the twenty-one brokerages that are covering the firm. One equities research analyst has rated the stock with a sell rating, sixteen have given a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $98.80.

A number of analysts have recently commented on PRGO shares. Vetr downgraded Perrigo from a “strong-buy” rating to a “buy” rating and set a $98.60 price objective on the stock. in a research note on Monday, August 15th. Guggenheim set a $125.00 target price on Perrigo and gave the stock a “buy” rating in a research report on Thursday, September 15th. RBC Capital Markets reiterated a “sector perform” rating and set a $92.00 price target on shares of Perrigo in a report on Tuesday, September 20th. Argus reiterated a “hold” rating on shares of Perrigo in a report on Tuesday, September 27th. Finally, Bank of America Corp. upgraded Perrigo from an “underperform” rating to a “neutral” rating in a report on Friday, November 11th.

In other Perrigo news, Director Gary K. Kunkle, Jr. sold 5,814 shares of the business’s stock in a transaction that occurred on Friday, September 9th. The shares were sold at an average price of $89.95, for a total transaction of $522,969.30. Following the completion of the transaction, the director now directly owns 31,501 shares in the company, valued at $2,833,514.95. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Thomas Farrington sold 1,110 shares of the business’s stock in a transaction that occurred on Monday, September 26th. The shares were sold at an average price of $96.76, for a total transaction of $107,403.60. Following the transaction, the executive vice president now owns 2,970 shares of the company’s stock, valued at $287,377.20. The disclosure for this sale can be found here. 4.47% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in PRGO. D.A. Davidson & CO. boosted its stake in Perrigo by 481.4% in the third quarter. D.A. Davidson & CO. now owns 6,454 shares of the company’s stock worth $593,000 after buying an additional 5,344 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Perrigo by 1.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 268,720 shares of the company’s stock valued at $24,811,000 after buying an additional 3,020 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in shares of Perrigo during the third quarter valued at $1,473,000. Notis McConarty Edward boosted its stake in shares of Perrigo by 11.5% in the third quarter. Notis McConarty Edward now owns 5,825 shares of the company’s stock valued at $538,000 after buying an additional 600 shares in the last quarter. Finally, Credit Suisse AG boosted its stake in shares of Perrigo by 13.0% in the third quarter. Credit Suisse AG now owns 260,344 shares of the company’s stock valued at $24,040,000 after buying an additional 29,930 shares in the last quarter. Institutional investors and hedge funds own 69.38% of the company’s stock.

Shares of Perrigo (NYSE:PRGO) traded up 0.98% during midday trading on Wednesday, hitting $86.63. The stock had a trading volume of 472,900 shares. Perrigo has a 52 week low of $79.72 and a 52 week high of $152.36. The stock has a 50 day moving average price of $87.46 and a 200-day moving average price of $91.83. The stock’s market capitalization is $12.42 billion.

Perrigo (NYSE:PRGO) last announced its earnings results on Thursday, November 10th. The company reported $1.65 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.07. The firm had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.28 billion. Perrigo had a positive return on equity of 10.78% and a negative net margin of 26.62%. The firm’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.76 EPS. Equities research analysts anticipate that Perrigo will post $6.98 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 13th. Shareholders of record on Friday, November 25th will be given a dividend of $0.145 per share. The ex-dividend date of this dividend is Tuesday, November 22nd. This represents a $0.58 annualized dividend and a yield of 0.68%. Perrigo’s dividend payout ratio (DPR) is presently -5.53%.

ILLEGAL ACTIVITY WARNING: “Perrigo Co. (PRGO) Given Consensus Recommendation of “Hold” by Analysts” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and republished in violation of United States & international copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2016/11/30/perrigo-co-prgo-given-consensus-recommendation-of-hold-by-analysts.html.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

5 Day Chart for NYSE:PRGO

Receive News & Stock Ratings for Perrigo Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Co. and related stocks with our FREE daily email newsletter.